Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid Tumors

NCT00606814 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors

Interventions

DRUG: IPI-504, docetaxel

Sponsor

Infinity Pharmaceuticals, Inc.